Seegene Q3 Operating Profit Up 21.2% to 11.6 Billion Won

Revenue of 123.1 billion won...up 8.4% year over year
Revenue from non-respiratory products rose 12.3% to 62.4 billion won

Seegene said on November 6 that it recorded consolidated revenue of 123.1 billion won and operating profit of 11.6 billion won in the third quarter of this year. These figures were up 8.4% and 21.2%, respectively, from the same period a year earlier.

Sales of major non-respiratory product lines, including human papillomavirus (HPV), sexually transmitted infections (STI), and gastrointestinal (GI) products, grew across the board compared with the same period last year, contributing to the overall increase in revenue.

Revenue from non-respiratory products rose 12.3% year over year to 62.4 billion won. By product line, sales increased 19.7% for HPV, 12.6% for GI, and 6.7% for STI. Seegene said, "We are diversifying our business foundation by expanding the share of revenue from non-respiratory products, supported by a broad portfolio of tests for infectious diseases."

By region, Europe accounted for 59.1% of total revenue, followed by Asia at 15.8%, Central and South America at 13%, Korea at 7.3%, and North America at 4.8%. Seegene is pursuing expansion in the global market, building on its revenue base in major overseas markets.

Kim Jeongyong, Seegene's head of finance, said, "Our major non-respiratory product lines are growing across the board, diversifying our revenue base. We will continue to expand the markets for our existing products while advancing next-generation diagnostic solutions to strengthen our medium- to long-term growth drivers."

This content was produced with the assistance of AI translation services.